Harnessing the Immune System to fight cancer

Takis main focus is the development of therapeutic cancer vaccines against tumor antigens which play a role in tumor development and maintenance.

To explore Takis opportunities, click here

Takis and Evvivax developing a 2019-nCoV Coronavirus vaccine

Rome, 27 January 2020 - Takis and Evvivax, two biotechnology companies present in the science park of Castel Romano, Rome announce their commitment for the development of innovative vaccines against 2019-nCoV, the new coronavirus originating in Wuhan, China. To date, the virus has caused 81 deaths and over 2,800 known infections and is rapidly expanding in various countries.

Application deadline: 31.12.2019

Start date: 01.03.2020
(or 01.04.2020)

<4 years after MSc, no PhD title,
<12 months in the hosting country in the last 3 years

Our team
is recognized

for the conception and implementation of a number of innovative technologies with the goal to improve in vivo gene transfer, regulation of gene expression and immunogenicity.


Takis as a CRO provides a variety of research services

in the areas of Oncology, Immunology, Infectious Diseases and novel preclinical models.


eit HEALTH - European Union

eit Health
Takis Biotech

Harnessing the Immune System to fight cancer.

Takis S.r.l.

Via Castel Romano, 100
00128 Rome - Italy
P. I.V.A. 10700711004

Follow us